Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
Daniel Wolff,Corey Cutler,Stephanie J Lee,Iskra Pusic,Henrique Bittencourt,Jennifer White,Mehdi Hamadani,Sally Arai,Amandeep Salhotra,Jose A Perez-Simon,Amin Alousi,Hannah Choe,Mi Kwon,Arancha Bermúdez,Inho Kim,Gerard Socié,Saurabh Chhabra,Vedran Radojcic,Timothy O'Toole,Chuan Tian,Peter Ordentlich,Zachariah DeFilipp,Carrie L Kitko,AGAVE-201 Investigators,Abir Bhattacharyya,Dries Deeren,Helene Schoemans,Gizelle Popradi,Su-Peng Yeh,Bor-Sheng Ko,Gerard Socie,Anne Huynh,Laetitia Souchet,Bruno Lioure,Edouard Forcade,Sandrine Loron,Matthias Stelljes,Ioanna Sakellari,Panagiotis Tsirigotis,Avichai Shimoni,Ron Ram,Tsila Rosenvald-Zuckerman,Batia Avni,Marco Zecca,Fabio Ciceri,Simona Sica Fondazione,Fulvio Porta,Ho-Jin Shin,Sebastian Giebel,Liang Piu,Manuel Jurado,Jamie Sanz Caballer,Maria Sola Soto,Carmen Martinez,Lucia Lopez,Jose Antonio Perez-Simon,Maria Bermudez Rodriguez,Rafael Duarte,Emma Nicholson,Anne Parker,Wendy Ingram,Eduardo Olavarria,Daniel Avenoso,Shernan Holtan,Stephanie Lee,Carrie Kitko,Antonio Di Stasi,Mohammad Abu Zaid,Daniel Couriel,Joseph Uberti,Trent Wang,Farhad Khimani,Aric Hall,Satyajit Kosuri,Molly Gallogly,Eric Tam,Tsiporah Shore,Annie Im,Mohamad Khawandanah,Arpita Gandhi,Betty Hamilton,Muthalgu Ramanathan,Muna Qayed,David Jacobsohn,Nosha Farhadfar,Pooja Khandelwal,Leonid Volodin,Dianna Howard,Michael Schuster,Mark Litzow,Dale G Schaar,Scott Solomon,Gabriela Motyckova,Madiha Iqbal,John Magenau
DOI: https://doi.org/10.1056/NEJMoa2401537
2024-09-19
Abstract:Background: Colony-stimulating factor 1 receptor (CSF1R)-dependent monocytes and macrophages are key mediators of chronic graft-versus-host disease (GVHD), a major long-term complication of allogeneic hematopoietic stem-cell transplantation. The CSF1R-blocking antibody axatilimab has shown promising clinical activity in chronic GVHD. Methods: In this phase 2, multinational, pivotal, randomized study, we evaluated axatilimab at three different doses in patients with recurrent or refractory chronic GVHD. Patients were randomly assigned to receive axatilimab, administered intravenously, at a dose of 0.3 mg per kilogram of body weight every 2 weeks (0.3-mg dose group), at a dose of 1 mg per kilogram every 2 weeks (1-mg dose group), or at a dose of 3 mg per kilogram every 4 weeks (3-mg dose group). The primary end point was overall response (complete or partial response) in the first six cycles; the key secondary end point was a patient-reported decrease in chronic GVHD symptom burden, as assessed by a reduction of more than 5 points on the modified Lee Symptom Scale (range, 0 to 100, with higher scores indicating worse symptoms). The primary end point would be met if the lower bound of the 95% confidence interval exceeded 30%. Results: A total of 241 patients were enrolled (80 patients in the 0.3-mg dose group, 81 in the 1-mg dose group, and 80 in the 3-mg dose group). The primary end point was met in all the groups; an overall response was observed in 74% (95% confidence interval [CI], 63 to 83) of the patients in the 0.3-mg dose group, 67% (95% CI, 55 to 77) of the patients in the 1-mg dose group, and 50% (95% CI, 39 to 61) of the patients in the 3-mg dose group. A reduction of more than 5 points on the modified Lee Symptom Scale was reported in 60%, 69%, and 41% of the patients in the three dose groups, respectively. The most common adverse events were dose-dependent transient laboratory abnormalities related to CSF1R blockade. Adverse events leading to discontinuation of axatilimab occurred in 6% of the patients in the 0.3-mg dose group, 22% in the 1-mg dose group, and 18% in the 3-mg dose group. Conclusions: Targeting CSF1R-dependent monocytes and macrophages with axatilimab resulted in a high incidence of response among patients with recurrent or refractory chronic GVHD. (Funded by Syndax Pharmaceuticals and Incyte; AGAVE-201 ClinicalTrials.gov number, NCT04710576.).